Drug Interactions between aducanumab and aspirin / diphenhydramine / phenylpropanolamine
This report displays the potential drug interactions for the following 2 drugs:
- aducanumab
- aspirin/diphenhydramine/phenylpropanolamine
Interactions between your drugs
aspirin aducanumab
Applies to: aspirin / diphenhydramine / phenylpropanolamine and aducanumab
MONITOR CLOSELY: Coadministration with drugs that can affect hemostasis such as anticoagulants, antiplatelet agents, and thrombolytics may potentiate the risk of bleeding complications observed with amyloid beta-directed antibody therapy. Use of monoclonal antibodies directed against aggregated forms of beta amyloid such as aducanumab, donanemab, and lecanemab has been associated with amyloid related imaging abnormalities (ARIA) with hemosiderin deposition (ARIA-H), including microhemorrhage, superficial siderosis, and intracerebral hemorrhage greater than 1 cm in diameter, the latter of which can be fatal. Based on limited clinical trial data, concomitant use of these monoclonal antibodies with an antithrombotic medication (aspirin, other antiplatelet agents, or anticoagulants) does not appear to significantly increase the risk of ARIA-H or intracerebral hemorrhage compared to use without an antithrombotic medication or placebo with an antithrombotic medication. However, the majority of antithrombotic exposures in trial patients were to aspirin only; therefore, no definitive conclusions regarding safety concerns can be drawn. In addition, patients with known risk factors for intracerebral hemorrhage were excluded from clinical trials.
MANAGEMENT: Due to the risk of potentially fatal intracerebral hemorrhage, caution and close monitoring are recommended with the use of antithrombotic or thrombolytic agents in patients receiving amyloid beta-directed antibody therapy, particularly those with risk factors for ARIA and intracerebral hemorrhage such as apolipoprotein E epsilon 4 carriers (approximately 15% of patients with Alzheimer's disease are apoE epsilon 4 homozygotes) or patients with baseline radiographic findings suggestive of cerebral amyloid angiopathy (e.g., evidence of prior intracerebral hemorrhage greater than 1 cm in diameter, at least two cerebral microhemorrhages, cortical superficial siderosis, vasogenic edema, diffuse white matter disease) or other lesions (e.g., aneurysm, vascular malformation). Because ARIA with edema (ARIA-E) can cause focal neurologic deficits that may mimic an ischemic stroke, clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy in patients being treated with an amyloid beta-directed antibody.
References (3)
- (2023) "Product Information. Leqembi (lecanemab)." Eisai Inc, 1
- (2024) "Product Information. Kisunla (donanemab)." Lilly, Eli and Company
- (2023) "Product Information. Aduhelm (aducanumab)." Biogen Idec Inc
Drug and food interactions
phenylpropanolamine food
Applies to: aspirin / diphenhydramine / phenylpropanolamine
GENERALLY AVOID: Alcohol may potentiate the central nervous system and cardiovascular effects of centrally-acting appetite suppressants. In one study, concurrent administration of methamphetamine (30 mg intravenously) and ethanol (1 gm/kg orally over 30 minutes) increased heart rate by 24 beats/minute compared to methamphetamine alone. This increases cardiac work and myocardial oxygen consumption, which may lead to more adverse cardiovascular effects than either agent alone. Subjective effects of ethanol were diminished in the eight study subjects, but those of methamphetamine were not affected. The pharmacokinetics of methamphetamine were also unaffected except for a decrease in the apparent volume of distribution at steady state.
MANAGEMENT: Concomitant use of centrally-acting appetite suppressants and alcohol should be avoided if possible, especially in patients with a history of cardiovascular disease. Patients should be counselled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (3)
- Mendelson J, Jones RT, Upton R, Jacob P 3rd (1995) "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther, 57, p. 559-68
- (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
- (2012) "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals
aspirin food
Applies to: aspirin / diphenhydramine / phenylpropanolamine
GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.
MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.
References (1)
- (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn
diphenhydrAMINE food
Applies to: aspirin / diphenhydramine / phenylpropanolamine
GENERALLY AVOID: Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous. In addition, the potential for abuse may be increased with the combination. The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system. No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load. However, one study found impairment of attention in subjects given atropine 0.5 mg or glycopyrrolate 1 mg in combination with alcohol.
MANAGEMENT: Alcohol should generally be avoided during therapy with anticholinergic agents. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.
References (1)
- Linnoila M (1973) "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol, 6, p. 107-12
phenylpropanolamine food
Applies to: aspirin / diphenhydramine / phenylpropanolamine
MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.
MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.
References (7)
- Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
- Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
- (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
- (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
- (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
- (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
- (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
aspirin food
Applies to: aspirin / diphenhydramine / phenylpropanolamine
One study has reported that coadministration of caffeine and aspirin lead to a 25% increase in the rate of appearance and 17% increase in maximum concentration of salicylate in the plasma. A significantly higher area under the plasma concentration time curve of salicylate was also reported when both drugs were administered together. The exact mechanism of this interaction has not been specified. Physicians and patients should be aware that coadministration of aspirin and caffeine may lead to higher salicylate levels faster.
References (1)
- Yoovathaworn KC, Sriwatanakul K, Thithapandha A (1986) "Influence of caffeine on aspirin pharmacokinetics." Eur J Drug Metab Pharmacokinet, 11, p. 71-6
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.